MUFG Americas’s CRISPR Therapeutics CRSP Stock Holding History

MUFG Americas’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10	Closed	-$1K	–	159
2022 Q3	$1K	Buy	+10	New	+$725	﹤0.01%	831

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MUFG Americas's CRSP Position: Q4 2022 in Review

MUFG Americas sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 10 shares — an estimated $1K sold.

MUFG Americas first reported a position in CRSP in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 396 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

MUFG Americas reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
MUFG Americas sold 10 CRISPR Therapeutics shares in Q4 2022, an estimated $1K.
MUFG Americas first reported a position in CRISPR Therapeutics in Q3 2022 and held it in 1 quarter.
MUFG Americas's CRISPR Therapeutics position peaked at $1K in Q3 2022.
396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on MUFG Americas's 13F filing for Q4 2022.